Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex (Interferon beta 1a) in Patients With Relapsing-Remitting Multiple Sclerosis

Trial Profile

Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex (Interferon beta 1a) in Patients With Relapsing-Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Daclizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms DECIDE
  • Sponsors Biogen Idec
  • Most Recent Events

    • 27 Jun 2017 Results assessing daclizumab in disease-modifying therapy-naive patients with active disease (n=1085) presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Results of post hoc analysis assessing treatment outcomes in DECIDE patients who are at high risk of transitioning to secondary progressive multiple sclerosis, presented at the 3rd Congress of the European Academy of Neurology.
    • 28 Apr 2017 Results assessing effectiveness of Daaclizumab in reduction of brain tissue loss in comparison with Interferon Beta- 1a presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top